Dublin, Aug. 16, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Nhl: Follicular Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. The follicular lymphoma (FL) market will continue to grow during 2016-25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies. This report addresses the following questions: - What will be driving the growth of the FL market during 2016-25? - Which market will be the most lucrative and which will experience fastest growth? - Which branded therapies will have the largest impact on the FL market? - When will generic and biosimilar therapies enter the market and what impact will they have on revenues? Key Topics Covered: FORECAST: FOLLICULAR LYMPHOMA - Copanlisib - Duvelisib - Gazyva (obinutuzumab) - Imbruvica (ibrutinib) - Revlimid (lenalidomide) - Rituxan (rituximab) - Treanda (bendamustine) - Zevalin (ibritumomab tiuxetan) - Zydelig (idelalisib) - Primary Research Methodology TREATMENT: FOLLICULAR LYMPHOMA - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends EPIDEMIOLOGY: FOLLICULAR LYMPHOMA - Disease Background - Sources and Methodology - Forecast: NHL Overall - Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL) - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: FOLLICULAR LYMPHOMA
- Product profile: Gazyva - Product profile: Rituxan - Product profile: Treanda - Product profile: Zevalin - Product profile: Zydelig PIPELINE: FOLLICULAR LYMPHOMA - Product profile (late stage): Arzerra - Product profile (late stage): Imbruvica - Product profile (late stage): Revlimid - Product profile (late stage): copanlisib - Product profile (late stage): duvelisib For more information about this report visit http://www.researchandmarkets.com/research/cd...follicular Related Topics: Lymphoma Drugs
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716